

Statement regarding use of non-GAAP financial measures

In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached financial statements.

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition - amortization of intangible assets: Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights.
- Severance – executive severance: Represents one-time severance expenses associated with the departure of executive officers of Myriad Genetics, Inc.
- Discontinued operations - One-time charges associated with the closing of business units.
- Acquisition costs – Closing and restructuring costs associated with acquired companies
- Tax expense associated with R&D tax credit reserves – One time net benefits associated with the release of R&D tax credit reserves.
- Tax impact related to equity compensation – Changes in effective tax rate based upon ASU 2016-09

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

**Reconciliation of GAAP to Non-GAAP Financial Measures
for the Three and Twelve Months ended June 30, 2016 and 2015**

(Unaudited data in millions, except per share amount)

	Three Months Ended		Twelve Months Ended	
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
<i>Revenue</i>	186.5	189.9	753.8	723.1
GAAP Cost of molecular diagnostic testing	\$ 34.2	\$ 32.0	\$ 132.8	\$ 132.8
GAAP Cost of pharmaceutical and clinical services	5.8	5.5	24.5	14.6
Acquisition - amortization of intangible assets	-	-	-	-
Non-GAAP COGS	\$ 40.0	\$ 37.5	\$ 157.3	\$ 147.4
Non-GAAP Gross Margin	79%	80%	79%	80%
GAAP Research and Development	\$ 19.5	\$ 18.7	\$ 70.6	\$ 75.5
Severance - executive severance	-	-	-	(0.4)
Discontinued operations	-	(0.1)	-	(0.3)
Acquisition - amortization of intangible assets	(0.1)	(0.1)	(0.4)	(0.3)
Non-GAAP R&D	\$ 19.4	\$ 18.5	\$ 70.2	\$ 74.5
GAAP Selling, General and Administrative	\$ 91.3	\$ 97.5	\$ 359.1	\$ 366.0
Severance - executive severance	-	(8.3)	-	(19.5)
Discontinued operations	-	(0.4)	-	(0.4)
Acquisition costs	(0.1)	-	(0.1)	-
Acquisition - amortization of intangible assets	(3.1)	(3.1)	(12.2)	(12.2)
Non-GAAP SG&A	\$ 88.1	\$ 85.7	\$ 346.8	\$ 333.9
GAAP Operating Income	\$ 35.7	\$ 36.2	\$ 166.8	\$ 134.2
Discontinued operations	-	0.5	-	0.7
Severance - executive severance	-	8.3	-	19.9
Acquisition costs	0.1	-	0.1	-
Acquisition - amortization of intangible assets	3.2	3.2	12.6	12.5
Non-GAAP Operating Income	\$ 39.0	\$ 48.2	\$ 179.5	\$ 167.3
Non-GAAP Operating Margin	21%	25%	24%	23%
GAAP Net Income	\$ 23.4	\$ 18.7	\$ 125.3	\$ 80.2
Severance - executive severance	-	8.3	-	19.9
Discontinued operations	-	0.8	-	1.0
Acquisition costs	0.1	-	0.1	-
Acquisition - amortization of intangible assets	3.2	3.2	12.6	12.5
Tax expense associated with R&D tax credit reserves	-	-	(6.0)	-
Tax impact related to equity compensation	(0.3)	-	(12.7)	-
Other tax expense	-	2.1	-	2.1
Tax expense associated with Non-GAAP adjustments	-	(3.7)	-	(7.7)
Non-GAAP Net Income	\$ 26.4	\$ 29.4	\$ 119.3	\$ 108.0
GAAP Diluted EPS	\$ 0.32	\$ 0.26	\$ 1.71	\$ 1.08
Non-GAAP Diluted EPS	\$ 0.36	\$ 0.41	\$ 1.63	\$ 1.45
<i>Diluted shares outstanding</i>	72.4	72.4	73.4	74.5

Free Cash Flow Reconciliation
(Unaudited data in thousands)

	Three Months Ended		Twelve Months Ended	
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
GAAP cash flow from operations	\$ 56.4	\$ 51.0	\$ 166.3	\$ 140.5
Capital expenditures	(2.2)	(2.0)	(5.0)	(23.9)
Free cash flow	<u>\$ 54.2</u>	<u>\$ 49.0</u>	<u>\$ 161.3</u>	<u>\$ 116.6</u>

Reconciliation of GAAP to Non-GAAP for Fiscal Year 2017 and Fiscal First-Quarter 2017
Financial Guidance

The Company's future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from guidance set forth below. Some of the factors that could affect the Company's financial results are stated in the safe harbor statement of this press release. More information on potential factors that could affect the Company's financial results are included under the heading "Risk Factors" contained in Item 1A in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

	<u>Fiscal Year 2017</u>
Diluted net income per share	
GAAP diluted net income per share	\$0.47 - \$0.57
Acquisition - amortization of intangible assets	0.36
Acquisition costs	0.17
Non-GAAP diluted net income per share	<u><u>\$1.00 - \$1.10</u></u>
	<u>Fiscal First-Quarter 2017</u>
Diluted net income per share	
GAAP diluted net income per share	\$0.14 - \$0.16
Acquisition - amortization of intangible assets	0.04
Acquisition costs	0.07
Non-GAAP diluted net income per share	<u><u>\$0.25 - \$0.27</u></u>